Regeneron Acquires 23andMe for $256 Million Amid Privacy Concerns and Data Breach Fallout

Regeneron Pharmaceuticals confirms its acquisition of 23andMe, the once-prominent consumer genetic testing firm, for $256 million through a bankruptcy auction. The transaction is expected to close in the third quarter of 2025, pending final court and regulatory approval. The deal excludes 23andMe’s telehealth subsidiary, Lemonaid Health, which will be discontinued as part of the restructuring.

Regeneron Pharmaceuticals is purchasing 23-and-Me through a bankruptcy auction. Matt Mattenson has more.

Founded in 2006, 23andMe rose to popularity with its direct-to-consumer DNA testing kits and personal genetic reports, collecting genetic data from over 15 million. . .